Information about Researcher Basia Lipert
Researcher: Basia Lipert
Information
| Role | Researcher |
|---|---|
| First name | Basia |
| Last name | Lipert |
| Country | New Zealand |
| Academic title | PhD |
| Organisation | University of Auckland |
| Thematic area/field | NZ – Life Sciences / NZ2 Genetics, genomics |
| Key words | functional genomics, biomarkers, antibody-drug conjugates, DNA damage |
More | |
| Short summary of activities and expertise | In my PhD research, I investigated an RNase Regnase-1 in the context of inflammation, cell differentiation and carcinogenesis. Focus of my current studies is on cancer therapy and biology. I use CRISPR/Cas9 functional genetic screens to find predictive biomarkers for precision medicine treatment of breast and head and neck cancer. In particular, I investigate sensitivity genes to HER2-targeting T-DM1 agent and to DNA-damaging drugs. |
| Relevant publications and/or research/innovation products | Hunter FW, Barker HR, LIPERT B, Rothé F, Gebhart G, Piccart-Gebhart MJ, Sotiriou Ch, Jamieson SMF. (2020) Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British Journal of Cancer, 122(5):603-612. IF 5.5 __________________ Hunter FW, LIPERT B, Siemens KN, Khan A, Barker HR, Ketela TW, Wilson WR, Lee TW, Jamieson SMF. Identification of TSC1 and TSC2 as potential determinants of sensitivity to trastuzumab emtansine. American Association for Cancer Research, online presentation 5853, 2020. (Abstract) __________________ Hay MP, Way WW, Dickson BD, LIPERT B, Lee TW, Wilson WR. Hypoxia activated prodrugs of DNA-PK inhibitors as radiosensitisers. 64th Annual Radiation Research Society Meeting, Chicago, USA, 2018. (Abstract) |
| Other relevant achievements | |
| Preferred Host Institution type | Academic, Research centre |
| Additional information | |
Contact | |
| basia.lipert@gmail.com | |
| Phone number | |
| Website | https://unidirectory.auckland.ac.nz/profile/blip884 |
